MedTrace Logo

Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate

NCT01222026 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2015-01-21

No results posted yet for this study

Summary

Patients with primary hyperparathyroidism (pHPT) with osteopenia and osteoporosis are treated with strontium ranelate/Ca+Vitamin-D or placebo/Ca+Vitamin D after successful surgical treatment of pHPT.

Strontium ranelate/Ca + Vitamin-D helps to regain bone mass in patients with osteopenia or osteoporosis after successful parathyroidectomy for pHPT and results in higher gain of BMD than placebo treated patients.

Conditions

Interventions

DRUG

Strontium Ranelate + Ca/Vitamin-D

2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D

DRUG

Placebo

Placebo 1000mg Calcium 800 IE Vitamin-D

Sponsors & Collaborators

  • National Bank of Austria

    collaborator OTHER_GOV

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Bruno Niederle, Prof., MD · Section of Endocrine Surgery, Department of Surgery, Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222026 on ClinicalTrials.gov